# A Study Of Atorvastatin For The Treatment Of High Cholesterol In Patients At High Risk Of Coronary Heart Disease (CHD)

> **NCT00644709** · PHASE4 · COMPLETED · sponsor: **Pfizer's Upjohn has merged with Mylan to form Viatris Inc.** · enrollment: 196 (actual)

## Conditions studied

- Dyslipidemias

## Interventions

- **DRUG:** Atorvastatin

## Key facts

- **NCT ID:** NCT00644709
- **Lead sponsor:** Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-09
- **Primary completion:** —
- **Final completion:** 2005-03
- **Target enrollment:** 196 (ACTUAL)
- **Last updated:** 2021-02-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00644709

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00644709, "A Study Of Atorvastatin For The Treatment Of High Cholesterol In Patients At High Risk Of Coronary Heart Disease (CHD)". Retrieved via AI Analytics 2026-07-12 from https://api.ai-analytics.org/clinical/NCT00644709. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*